219 related articles for article (PubMed ID: 20551053)
1. PIK3CA mutations in in situ and invasive breast carcinomas.
Miron A; Varadi M; Carrasco D; Li H; Luongo L; Kim HJ; Park SY; Cho EY; Lewis G; Kehoe S; Iglehart JD; Dillon D; Allred DC; Macconaill L; Gelman R; Polyak K
Cancer Res; 2010 Jul; 70(14):5674-8. PubMed ID: 20551053
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
[TBL] [Abstract][Full Text] [Related]
3. Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.
Bergholtz H; Kumar S; Wärnberg F; Lüders T; Kristensen V; Sørlie T
Cancer Rep (Hoboken); 2020 Jun; 3(3):e1248. PubMed ID: 32671987
[TBL] [Abstract][Full Text] [Related]
4. Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions.
Ang DC; Warrick AL; Shilling A; Beadling C; Corless CL; Troxell ML
Mod Pathol; 2014 May; 27(5):740-50. PubMed ID: 24186142
[TBL] [Abstract][Full Text] [Related]
5. PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.
Sakr RA; Weigelt B; Chandarlapaty S; Andrade VP; Guerini-Rocco E; Giri D; Ng CK; Cowell CF; Rosen N; Reis-Filho JS; King TA
Clin Cancer Res; 2014 May; 20(9):2326-37. PubMed ID: 24634376
[TBL] [Abstract][Full Text] [Related]
6. PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.
Kalinsky K; Heguy A; Bhanot UK; Patil S; Moynahan ME
Breast Cancer Res Treat; 2011 Sep; 129(2):635-43. PubMed ID: 21617917
[TBL] [Abstract][Full Text] [Related]
7. Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: Repertoire of somatic genetic alterations and clonal relationships.
Sakr RA; Schizas M; Carniello JV; Ng CK; Piscuoglio S; Giri D; Andrade VP; De Brot M; Lim RS; Towers R; Weigelt B; Reis-Filho JS; King TA
Mol Oncol; 2016 Feb; 10(2):360-70. PubMed ID: 26643573
[TBL] [Abstract][Full Text] [Related]
8. Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions.
Troxell ML; Brunner AL; Neff T; Warrick A; Beadling C; Montgomery K; Zhu S; Corless CL; West RB
Mod Pathol; 2012 Jul; 25(7):930-7. PubMed ID: 22460814
[TBL] [Abstract][Full Text] [Related]
9. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
Li H; Zhu R; Wang L; Zhu T; Li Q; Chen Q; Wang H; Zhu H
Exp Mol Pathol; 2010 Feb; 88(1):150-5. PubMed ID: 19818761
[TBL] [Abstract][Full Text] [Related]
10. Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.
Kehr EL; Jorns JM; Ang D; Warrick A; Neff T; Degnin M; Lewis R; Beadling C; Corless CL; Troxell ML
Hum Pathol; 2012 Dec; 43(12):2207-12. PubMed ID: 22705004
[TBL] [Abstract][Full Text] [Related]
11. The PIK3CA gene is mutated with high frequency in human breast cancers.
Bachman KE; Argani P; Samuels Y; Silliman N; Ptak J; Szabo S; Konishi H; Karakas B; Blair BG; Lin C; Peters BA; Velculescu VE; Park BH
Cancer Biol Ther; 2004 Aug; 3(8):772-5. PubMed ID: 15254419
[TBL] [Abstract][Full Text] [Related]
12. Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients.
Ahmad F; Badwe A; Verma G; Bhatia S; Das BR
Med Oncol; 2016 Jul; 33(7):74. PubMed ID: 27282497
[TBL] [Abstract][Full Text] [Related]
13. PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [
Magometschnigg H; Pinker K; Helbich T; Brandstetter A; Rudas M; Nakuz T; Baltzer P; Wadsak W; Hacker M; Weber M; Dubsky P; Filipits M
Mol Imaging Biol; 2019 Oct; 21(5):991-1002. PubMed ID: 30652258
[TBL] [Abstract][Full Text] [Related]
14. PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.
Flatley E; Ang D; Warrick A; Beadling C; Corless CL; Troxell ML
Hum Pathol; 2013 Jul; 44(7):1320-7. PubMed ID: 23352210
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of PIK3CA mutations as a biomarker in Chinese breast carcinomas from Western China.
Cheng J; Fu S; Wei C; Tania M; Khan MA; Imani S; Zhou B; Chen H; Xiao X; Wu J; Fu J
Cancer Biomark; 2017; 19(1):85-92. PubMed ID: 28269754
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
Troxell ML; Levine J; Beadling C; Warrick A; Dunlap J; Presnell A; Patterson J; Shukla A; Olson NR; Heinrich MC; Corless CL
Mod Pathol; 2010 Jan; 23(1):27-37. PubMed ID: 19898424
[TBL] [Abstract][Full Text] [Related]
17. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.
Yamamoto S; Tsuda H; Takano M; Tamai S; Matsubara O
Mod Pathol; 2012 Apr; 25(4):615-24. PubMed ID: 22157930
[TBL] [Abstract][Full Text] [Related]
18. p53 mutations and expression in breast carcinoma in situ.
Lukas J; Niu N; Press MF
Am J Pathol; 2000 Jan; 156(1):183-91. PubMed ID: 10623666
[TBL] [Abstract][Full Text] [Related]
19. Mutational hotspot in exon 20 of PIK3CA in breast cancer among Singapore Chinese.
Liang X; Lau QC; Salto-Tellez M; Putti TC; Loh M; Sukumar S
Cancer Biol Ther; 2006 May; 5(5):544-8. PubMed ID: 16582596
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients.
Karakas B; Colak D; Kaya N; Ghebeh H; Al-Qasem A; Hendrayani F; Toulimat M; Al-Tweigeri T; Park BH; Aboussekhra A
Cancer Biol Ther; 2013 Oct; 14(10):888-96. PubMed ID: 23982433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
